Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Weiz – page 28

435 clinical trials in Weiz, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Weiz at a glance
435
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

435 trials in Weiz

Open in trial search

B-cell lymphoma+2

Not recruiting

Study Comparing Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:GWT-Tud GmbH

Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Universitaetsklinikum Ulm AöR

Hepatic cancer+1

Not recruiting

Study on Atezolizumab for Patients with Lung and Liver Cancer Using Digital Health Solutions

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study on Elinzanetant for Treating Hot Flashes in Women with or at High Risk for Hormone-Receptor Positive Breast Cancer

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elinzanetant
  • Sponsor:Bayer Consumer Care AG

Gastric cancer

Not recruiting

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Study on Xevinapant and Radiotherapy for High-Risk Head and Neck Cancer Patients Unable to Take High-Dose Cisplatin

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Xevinapant
  • Sponsor:Merck Healthcare KGaA

Study of Nivolumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of Nivolumab and Ipilimumab for Patients with Advanced Liver Cancer (Hepatocellular Carcinoma) as First-Line Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Effectiveness of Apalutamide in Men with Castration-Resistant Prostate Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Aragon Pharmaceuticals Inc.

Malignant melanoma

Not recruiting

Study of Fianlimab and Cemiplimab for Patients with Untreated Advanced Melanoma

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Weiz

What the registry says about research in the country

01 Breast Cancer Research

Clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative breast cancer, investigating innovative therapeutic approaches for patients with high recurrence risk.

  • Node-positive breast cancer treatment
  • Endocrine therapy optimization
  • Early-stage breast cancer management

Research aims to improve disease-free survival rates through targeted therapeutic interventions.

02 Endocrine Therapy Studies

Investigating the effectiveness of elacestrant compared to standard endocrine treatments for breast cancer patients, with a focus on improving long-term outcomes.

  • Comparative treatment efficacy
  • Invasive cancer-free survival
  • Gender-inclusive research

Studies evaluate novel therapeutic approaches for both women and men with hormone-sensitive breast cancer.

03 Advanced Treatment Protocols

Evaluation of palbociclib in combination with standard endocrine therapy, exploring enhanced treatment strategies for early-stage breast cancer.

  • Combination therapy assessment
  • Long-term treatment outcomes
  • Risk reduction strategies

Research focuses on improving standard treatment protocols through innovative drug combinations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.